- In July 2024, DELFI Diagnostics revealed that it secured an equity investment from the Merck Global Health Innovation Fund. This funding will be used to expedite the development of DELFI's AI-driven fragmentomics platform for cancer screening. The collaboration aims to enhance diagnostic capabilities and improve cancer detection methodologies
- In May 2024, Quest Diagnostics announced the separation of PathAI's digital pathology laboratory to enhance its focus on artificial intelligence integration. This strategic move aims to accelerate the adoption of AI technologies within its operations. The initiative is expected to strengthen Quest Diagnostics' capabilities in digital pathology and improve diagnostic accuracy
- In February 2023, F. Hoffmann-La Roche announced an expansion of its collaboration with Janssen to enhance personalized healthcare initiatives. This partnership will emphasize the development of companion diagnostics, aiming to improve treatment outcomes for patients. The expanded collaboration reflects both companies' commitment to advancing tailored therapeutic approaches in the healthcare sector
- In November 2023, Abbott obtained FDA approval for its HPV test designed for use with the Alinity m platform. This test enables primary screening for HPV and identifies high-risk types associated with cancer. The approval enhances Abbott's offerings in cervical cancer prevention and diagnosis
- In 2022, Precipio, Inc. established a distribution agreement for its HemeScreen product with a significant distribution partner in the U.S. The company is actively pursuing a comprehensive expansion strategy for HemeScreen, focusing on physician-owned laboratories, national and regional hospital networks, and reference labs. This multi-faceted approach aims to enhance the reach and availability of HemeScreen across various healthcare settings
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Consumables, and Instruments), Technology (IVD Testing, Imaging, and Biopsy Technique), Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, and Others), End User (Diagnostic Centres, Hospitals and Clinics, Research Institutes, and Others) – Industry Trends and Forecast to 2031
.
The Global Cancer Diagnostics Market size was valued at USD 17.98 USD Billion in 2023.
The Global Cancer Diagnostics Market is projected to grow at a CAGR of 7.7% during the forecast period of 2024 to 2031.
The major players operating in the market include Abbott, DiagnoCure , Thermo Fisher Scientific, Illumina , QIAGEN, F. Hoffmann-La Roche Ltd, Agilent Technologies , Quest Diagnostics ,orporated., Merck KGaA, Hologic , BD., GSK plc., Novartis AG, Bristol-Myers Squibb Company, Lilly, Pfizer , Genomic Health , bioMérieux SA, Astellas Pharma , Myriad Genetics ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
